Followers | 385 |
Posts | 20,945 |
Boards Moderated | 0 |
Alias Born | 04/05/2013 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EVAR AND EBIO both have extremely low SS.
EVAR HAS BIG NEWS OUT THIS MORNING..READ BELOW...
IRVINE, Calif. , Jan. 21, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc.
(NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair
(EVAR) of abdominal aortic aneurysms (AAAs), today announced that its new
Altura® Endograft System for AAA repair will be featured in a live clinical case
presentation for the first time at the 12th annual Leipzig Interventional Course
(LINC) being held at the Trade Fair Leipzig, in Leipzig, Germany , January 26-29,
2016 .
In addition, both of its endovascular stent grafts, Aorfix™ and Altura, will be
featured in scientific presentations. The Altura Endograft System has CE Mark
approval and is specifically designed to simplify treatment in patients with
standard AAA anatomy. Aorfix is the first and only endovascular stent graft
with global approvals for the treatment of patients with aortic neck angulations
up to 90 degrees.
Lombard Medical is hosting an Innovations in EVAR symposium in the Main Arena on
Wednesday, January 27, 2016 , from 9:30 to 11:00 a.m. featuring a live clinical
case transmission using the new Altura Endograft System by Andrej Schmidt , MD,
from Leipzig University Hospital .
“LINC 2016 is a great platform to showcase the Altura Endograft’s revolutionary
approach to EVAR with its simplified delivery and precise placement features in
a live clinical case presentation,” said CEO Simon Hubbert . “Altura is a highly
differentiated repositionable stent system which requires no contralateral limb
cannulation delivered in a 14F ultra low profile delivery catheter. A broad
range of patients can be treated with only six product codes, which simplifies
case planning and inventory management.”
The Altura Endograft System will be featured in the following scientific presentations at LINC on January 27, 2016 :
Main Arena 2
9:30 a.m. An Introduction to Altura: A new innovative ultra-low profile
aortic stent graft Speaker: Dierk Scheinert , MD, University of
Leipzig
10:05 a.m. Early experience and clinical data with the Altura AAA stent
graft. Announcing the new Altura registry ‘Altitude’ Speaker:
Albrecht Krämer, MD, Pontificia Universidad Catolica de Chile
The Aorfix Endovascular Stent Graft will be featured in the following scientific presentations at LINC on January 27, 2016 :
Main Arena 2
10:15 a.m. Aorfix treats the simplest to the most complex anatomies with
the advanced IntelliFlex™ LP delivery system Speaker: Andrew Holden ,
MD, Auckland City Hospital
10:50 a.m. Aorfix PYTHAGORAS US trial three year outcomes Speaker: Mahmoud Malas , MD, Johns Hopkins Bayview Medical Centre
About Altura Endograft SystemThe Altura system represents a paradigm shift in
endograft design that offers a simple and predictable treatment option for
standard AAA anatomy. Delivered via an ultra-low profile 14F catheter, it allows
for repositioning during deployment and accurate graft placement at each renal
artery enabling physicians to utilize all of the available aortic neck. It also
eliminates the need for cannulation that results in a simple, safe and
consistent deployment with predictable and shorter procedure times. With just 6
product sizes, the Altura system allows the majority of patients who present for
EVAR repair to be treated quickly with minimal hospital stay and recovery
times.
The Altura system received CE Mark in 2015. Lombard Medical plans to launch the
device in Europe in January 2016 with a broader international roll out later the
same year. In the U.S., Lombard intends to file for an IDE (Investigational
Device Exemption) from the FDA in 2016 with the intent to begin recruitment for
a U.S. clinical study later in 2016.
About Aorfix™ Endovascular Stent GraftAorfix™ is an endovascular stent graft
system for treating infra-renal aortic and aorto-iliac aneurysms, also known as
abdominal aortic aneurysms (AAAs). When placed within the aneurysm, Aorfix
creates an internal bypass of the aneurysm to reduce the risk of rupture. Aorfix
is the first and only endovascular stent graft with global approvals for the
treatment of patients with aortic neck angulations up to 90 degrees. Aorfix
features an exclusive helical and circular design that allows it to conform to
the natural contours of human anatomy, including aortic necks with high
angulations and iliac arteries with extreme bends. Aorfix has been evaluated in
three studies and used in more than 4,000 procedures worldwide. Aorfix received
FDA approval in 2013, and is commercially available in U.S., U.K. , Germany ,
Spain , Italy , Austria , Switzerland , the Czech Republic , Russia , Greece , Canada ,
Mexico , Brazil , Japan , Hong Kong , Poland , New Zealand , Argentina , Sweden ,
Colombia , Ireland , Chile , Peru , and Uruguay.
About Lombard Medical , Inc. Lombard Medical, Inc. is an Irvine, CA -based medical
device company focused on device solutions for the $1.7 billion per year
abdominal aortic aneurysm repair market. The Company’s lead product, Aorfix™, is
an endovascular stent graft which has been specifically designed to solve the
problems that exist in treating complex tortuous anatomies, which are often
present in advanced AAA disease. Aorfix has been used to treat more than 4,000
patients worldwide. Aorfix™, is the only endovascular stent graft cleared by the
U.S. Food and Drug Administration ( FDA ) for the treatment of AAAs with
angulation at the neck of the aneurysm of up to 90 degrees providing physicians
in the U.S. with the only ‘on-label’ endovascular treatment option for patients
with this complex AAA anatomy. All other approved grafts are only cleared by the
FDA for the treatment of neck angulation up to 60 degrees. For more information,
please visit www.lombardmedical.com.
Forward-Looking StatementsThis announcement contains forward-looking statements
that reflect the Company’s current expectations regarding future events. These
forward-looking statements generally can be identified by the use of words or
phrases such as “believe,” “expect,” “future,” “anticipate,” “look forward to,”
“intend,” “plan,” “foresee,” “may,” “should,” “will,” “estimates,” “outlook,”
“potential,” “optimistic,” “confidence,” “continue,” “evolve,” “expand,”
“growth” or words and phrases of similar meaning. Statements that describe
objectives, plans or goals also are forward-looking statements. Forward-looking
statements are subject to risks, management assumptions and
uncertainties. Actual results could differ materially from those projected
herein and depend on a number of factors, including the success of the Company’s
research and development and commercialization strategies, the uncertainties
related to the regulatory process and the acceptance of the Company’s products
by hospitals and other medical professionals, the uncertainty of estimated
revenues and profits, the uncertainty of current domestic and international
economic conditions that could adversely affect the level of demand for the
Company’s products and increased volatility in foreign exchange rates, the
inability to raise additional funds, and the risks, uncertainties and other
factors described under the heading “Risk Factors” in the Company’s Form 20-F
filed with the Securities and Exchange Commission dated April 29 , 2015. Readers
are urged to consider these factors carefully in evaluating the forward-looking
statements. The forward-looking statements included herein are made only as of
the date of this report and the Company undertakes no obligation to update
these
statements in the future.
For further information:
Lombard Medical, Inc. Simon Hubbert , Tel: +1 949 379 3750 /
Good morning chance...
If this reaches $5.00 I will be a buyer.
I like ASTI, but hate and I mean HATE the continued dilution.
No debt, no dilution and very small SS!
Markets rallying, good!
Bollies pinching together!
I'm watching but waiting for oil to bottom.
EBIO .4549 up!
Get your EBIO!
Ready! EBIO
Picked up some .44s.
EBIO bid building
I myself believe there will be a merger in the works.
Yep, checked that put last night.
Good day all! Time to get out and stay out of the market!
Yep!
EBIO was $2.36 yesterday, let's send it back above $1 today!
Not to mention a very small share structure!
Setting for a huge run!
EBIO bounce today! Way, way oversold!
EBIO going to be fun...,
Actually I expect a merger to take place!
My thought as well.
Add a few more myself and will add again EOD
Hey ash attorneys need to eat too! Lol
Anything to bloodsuck money from companies.
Well you will need to cover soon.
Yes sir.
EBIO weeeeee time
EBIO comith the Bounce.
Chart is setting up for a nice run!
I think 1.71?
I would not want to be short right here!
I read that too.
Yes and IMO will bounce..
Thanks for the .0803s
I agree
They are getting there for sure